Latest Imugene News & Updates

See the latest news and media coverage for Imugene. We track all announcements, press releases, and industry mentions in real time, all in one place.

Imugene

Clinical-stage immuno-oncology company

imugene.com

Headquarters: Sydney, Australia
Founded year: 2013
Company type: Public company
Number of employees: 50–200

Last updated Today

Latest news about Imugene

In short: Imugene achieved high response rates in its azer-cel Phase 1b trial and received FDA Fast Track Designation for specific blood cancer indications.

Company announcements

June 9 Imugene

Imugene's azer-cel receives FDA Fast Track Designation for blood cancers.

The designation applies to CLL/SLL and MZL indications with high response rates in Phase 1b trial.

June 5 Imugene

Imugene reports strongest ASCO data

The biotech firm presented promising CAR-T cell therapy results at ASCO 2026 and is planning next steps.

May 30 Imugene

Imugene's azer-cel achieves 81% overall response rate

Phase 1b dose expansion cohort in 19 relapsed/refractory blood cancer patients also showed 100% response in several subtypes.

April 9 Imugene

Imugene's azer-cel data selected for ASCO oral presentation

The presentation occurs at the 2026 ASCO Annual Meeting in Chicago. Details release on April 21, 2026.

Media coverage

June 9 Yahoo Finance

FDA Fast Track opens new path for Imugene's Azer-cel - ICYMI

Imugene Ltd (ASX:IMU, OTC:IUGNF, FRA:ILA) earlier this week announced that the US Food and Drug Administration (FDA) granted Fast Track Designation to its allogeneic CAR...

June 1 Yahoo

Imugene presents azer-cel data at ASCO as trial expands into new cohort

Imugene Ltd (ASX:IMU, OTC:IUGNF, FRA:ILA) has presented new Phase 1b data for its azer-cel cell therapy at the 2026 American Society of Clinical Oncology (ASCO...

May 28 Yahoo Finance

Imugene doses first patient in BTKi combination cohort for azer-cel study

Imugene Ltd (ASX:IMU, OTC:IUGNF, FRA:ILA) has dosed the first patient in the Bruton Tyrosine Kinase inhibitor (BTKi) combination cohort of its Phase 1b azer-cel study...

May 22 The Globe and Mail

Imugene's Off-the-Shelf CAR T Azer-cel Delivers 81% Response Rate in Early ASCO Data

Imugene has reported promising Phase 1b data for azer-cel, its allogeneic CD19 CAR T-cell therapy, in a CAR T-naïve cohort of patients with relapsed or...

Never miss news about Imugene

Track Imugene and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

Imugene competitors & trending companies

Browse news for competitors to Imugene and other trending companies.